

Satoshi Yuki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3372069/publications.pdf>

Version: 2024-02-01

130
papers

1,058
citations

567281
15
h-index

501196
28
g-index

136
all docs

136
docs citations

136
times ranked

1498
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201). <i>Oncologist</i> , 2022, 27, 340-e374.	3.7	2
2	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1136-1146.	7.0	62
3	The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. <i>Cancer Medicine</i> , 2022, , .	2.8	2
4	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. <i>JCO Precision Oncology</i> , 2022, 6, e2100383.	3.0	8
5	Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer. <i>Supportive Care in Cancer</i> , 2022, , 1.	2.2	2
6	Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603. <i>Oncologist</i> , 2022, 27, e642-e649.	3.7	8
7	Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100535.	3.0	29
8	Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. <i>Targeted Oncology</i> , 2022, , 1.	3.6	1
9	Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer. <i>BMJ Open</i> , 2022, 12, e048833.	1.9	1
10	Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in <i>RAS</i> wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3530-3530.	1.6	0
11	Plasma <i>RAS</i> dynamics and anti-EGFR rechallenge efficacy in patients with <i>RAS/BRAF</i> wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3518-3518.	1.6	11
12	Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 113-120.e1.	2.3	22
13	FMS–like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 314-322.	3.9	8
14	Evaluating the intratumor microbiome of pancreatic ductal adenocarcinoma (PDAC) by analyzing the fresh frozen tissues obtained by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA).. <i>Journal of Clinical Oncology</i> , 2021, 39, 418-418.	1.6	0
15	Translational research of VOLTAGE-A: Efficacy predictors of preoperative chemoradiotherapy and consolidation nivolumab in patients with both microsatellite stable and microsatellite instability-high locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 100-100.	1.6	6
16	Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin–based or irinotecan–based therapy for colorectal cancer. <i>Cancer Science</i> , 2021, 112, 1567-1578.	3.9	5
17	Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 207-211.	0.7	2
18	Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). <i>Frontiers in Oncology</i> , 2021, 11, 576036.	2.8	4

#	ARTICLE	IF	CITATIONS
19	Discovery of a potential predictive marker for eribulin treatment and novel target genes in BRAF V600E mutant metastatic colorectal cancer using an AI-driven RNA-seq analysis platform: Translational research of the BRAVERY study (EPOC1701).. Journal of Clinical Oncology, 2021, 39, e15532-e15532.	1.6	0
20	Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study.. Journal of Clinical Oncology, 2021, 39, 3529-3529.	1.6	1
21	A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). Oncologist, 2021, 26, e1675-e1682.	3.7	3
22	REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. BMC Cancer, 2021, 21, 674.	2.6	19
23	Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report. Case Reports in Oncology, 2021, 14, 806-811.	0.7	3
24	Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. Frontiers in Oncology, 2021, 11, 688709.	2.8	5
25	The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. Oncologist, 2021, 26, 845-853.	3.7	26
26	Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. European Journal of Cancer, 2021, 154, 296-306.	2.8	5
27	Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer. International Journal of Clinical Oncology, 2021, 26, 2025-2028.	2.2	3
28	Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. Clinical Colorectal Cancer, 2021, 20, e173-e184.	2.3	7
29	Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC.. Journal of Clinical Oncology, 2021, 39, 120-120.	1.6	1
30	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nature Medicine, 2021, 27, 1899-1903.	30.7	110
31	Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. Cancer Chemotherapy and Pharmacology, 2020, 85, 217-223.	2.3	13
32	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). Clinical Cancer Research, 2020, 26, 5887-5894.	7.0	44
33	Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study. International Journal of Clinical Oncology, 2020, 25, 1800-1806.	2.2	1
34	Practical considerations in the use of regorafenib in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095686.	3.2	16
35	Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603). Oncology, 2020, 98, 719-726.	1.9	0
36	Translational research of voltage-A1: Efficacy predictors of preoperative chemoradiotherapy and subsequent nivolumab monotherapy in patients with microsatellite-stable locally advanced rectal cancer.. Journal of Clinical Oncology, 2020, 38, 4073-4073.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.. Journal of Clinical Oncology, 2020, 38, 4100-4100.	1.6	40
38	Scoop: Multicenter phase I/II trial of BBI608 and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503).. Journal of Clinical Oncology, 2020, 38, 107-107.	1.6	3
39	Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2020, 38, 169-169.	1.6	4
40	Plasma VEGF-D and PlGF levels according to prior use of biologics among metastatic colorectal cancer: Preliminary results from GI-SCREEN CRC-Ukit study.. Journal of Clinical Oncology, 2020, 38, 178-178.	1.6	5
41	HGCSG 1301: A multicenter, double-blind, randomized controlled phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer treated with IRIS/Bev as second-line therapyâ€”Updated analysis of antitumor efficacy.. Journal of Clinical Oncology, 2020, 38, 108-108.	1.6	1
42	HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.. Journal of Clinical Oncology, 2020, 38, TPS4668-TPS4668.	1.6	0
43	The impact of single-hetero UGT1A1 on clinical outcomes of irinotecan monotherapy in gastric cancer after fluoropyrimidine, platinum, and taxanes: Multicenter retrospective study.. Journal of Clinical Oncology, 2020, 38, 296-296.	1.6	0
44	A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of albumin-bilirubin (ALBI) grade.. Journal of Clinical Oncology, 2020, 38, 415-415.	1.6	6
45	VOLTAGE-B study: Nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy.. Journal of Clinical Oncology, 2020, 38, 100-100.	1.6	1
46	Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for nextâ€”generation sequencing. Biomedical Reports, 2019, 11, 171-180.	2.0	4
47	One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. Oncologist, 2019, 24, 1593-1600.	3.7	21
48	Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy. BMC Cancer, 2019, 19, 255.	2.6	16
49	Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. ESMO Open, 2019, 4, e000584.	4.5	7
50	Voltage: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer.. Journal of Clinical Oncology, 2019, 37, 3606-3606.	1.6	12
51	Retrospective multicenter study for assessment of association between imaging change and outcome after treatment of regorafenib: KSCC1603.. Journal of Clinical Oncology, 2019, 37, 509-509.	1.6	1
52	Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.. Journal of Clinical Oncology, 2019, 37, 578-578.	1.6	1
53	Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer.. Journal of Clinical Oncology, 2019, 37, 84-84.	1.6	1
54	A retrospective analysis of neoadjuvant chemotherapy followed by surgery or definitive chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 115-115.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Update result of HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 359-359.	1.6	0
56	HGCSG 1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer.. Journal of Clinical Oncology, 2019, 37, TPS183-TPS183.	1.6	0
57	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). Oncology, 2018, 94, 289-296.	1.9	5
58	Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 198-205.	2.3	57
59	Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN.. Journal of Clinical Oncology, 2018, 36, 12094-12094.	1.6	9
60	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology, 2018, 36, 3530-3530.	1.6	10
61	The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).. Journal of Clinical Oncology, 2018, 36, 4050-4050.	1.6	13
62	A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of tumor location.. Journal of Clinical Oncology, 2018, 36, 802-802.	1.6	1
63	VOLTAGE: Multicenter phase 1b/II study of nivolumab monotherapy and subsequent radical surgery after preoperative chemoradiotherapy with capecitabine in patients with locally advanced rectal cancer.. Journal of Clinical Oncology, 2018, 36, TPS878-TPS878.	1.6	3
64	A Case Report of Successful Conversion Therapy with XELOX + Bevacizumab in a Patient with AFP-producing Colon Cancer and Synchronous Liver Metastases. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2018, 43, 845-854.	0.0	0
65	A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of cases of prior regorafenib.. Journal of Clinical Oncology, 2018, 36, 832-832.	1.6	0
66	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology, 2018, 36, 760-760.	1.6	0
67	Safety of administration of bevacizumab within a week from placement of a totally implantable central venous port system.. Journal of Clinical Oncology, 2018, 36, 589-589.	1.6	0
68	Predictive value of tumor growth rate during previous treatment for tumor response to regorafenib (REGO) and trifluridine/tipiracil (TFTD) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 766-766.	1.6	0
69	Survival outcome in HER2-amplified metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 642-642.	1.6	9
70	The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit.. Journal of Clinical Oncology, 2018, 36, TPS885-TPS885.	1.6	0
71	Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.. Journal of Clinical Oncology, 2018, 36, 10094-10094.	1.6	0
72	A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01). Oncologist, 2017, 22, 592-600.	3.7	30

#	ARTICLE	IF	CITATIONS
73	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. <i>British Journal of Cancer</i> , 2017, 117, 1450-1458.	6.4	52
74	Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 566-571.	1.4	67
75	Regorafenib (REG) versus trifluridine/tipiracil (TAS-102) as salvage-line in patients with metastatic colorectal cancer refractory to standard chemotherapies (REGOTAS): A propensity score analysis from a JSCCR multicenter observational study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3540-3540.	1.6	2
76	A phase II study (KSCC/HGCSG/CCOG/PerSeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4059-4059.	1.6	2
77	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3623-TPS3623.	1.6	2
78	Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205.. <i>Journal of Clinical Oncology</i> , 2017, 35, 151-151.	1.6	2
79	Updated analysis: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancerâ€”HGCSG1401.. <i>Journal of Clinical Oncology</i> , 2017, 35, 778-778.	1.6	6
80	A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting: ESPRESSO-02/HGCSG1602.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS809-TPS809.	1.6	0
81	North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003).. <i>Journal of Clinical Oncology</i> , 2017, 35, 807-807.	1.6	0
82	Systematic review and individual patient data based meta-analysis of palonosetron trials for chemotherapy induced nausea and vomiting.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21688-e21688.	1.6	0
83	The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan, GI-screen: Efficient identification of cancer genome alterations in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4041-4041.	1.6	0
84	Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience. <i>Journal of Gastric Cancer</i> , 2016, 16, 177.	2.5	2
85	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. <i>Gastric Cancer</i> , 2016, 19, 183-191.	5.3	95
86	A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402).. <i>Journal of Clinical Oncology</i> , 2016, 34, 10127-10127.	1.6	3
87	The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3591-3591.	1.6	4
88	A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3632-TPS3632.	1.6	1
89	Updated analysis: Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802)â€™Sub-group analysis by KRAS Exon2 status.. <i>Journal of Clinical Oncology</i> , 2016, 34, 522-522.	1.6	0
90	Prospective observational study for the impact of short-term periodic intravenous steroid premedication for gastrointestinal cancer chemotherapy on bone metabolism.. <i>Journal of Clinical Oncology</i> , 2016, 34, 523-523.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSC0802â€”Analysis of early tumor shrinkage (ETS).. Journal of Clinical Oncology, 2016, 34, 753-753.	1.6	0
92	Phase II trial of bolus 5-FU/I-LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSC1502).. Journal of Clinical Oncology, 2016, 34, TPS177-TPS177.	1.6	0
93	Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSC0802): Sub-group analysis by the GERCOR index.. Journal of Clinical Oncology, 2016, 34, 743-743.	1.6	0
94	Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSC0902â€”Comparison of administration interval in cetuximab treatment.. Journal of Clinical Oncology, 2016, 34, 771-771.	1.6	0
95	The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)â€”GI-SCREEN 2013-01-CRC sub-study.. Journal of Clinical Oncology, 2016, 34, 3573-3573.	1.6	1
96	Update analysis: Prospective observational study for the impact of short-term periodic steroid premedication for cancer chemotherapy on bone metabolismâ€”ESPRESSO-01 study.. Journal of Clinical Oncology, 2016, 34, e18145-e18145.	1.6	0
97	Openâ€”label, randomized, comparative, phase <sc>III</sc> study on effects of reducing steroid use in combination with Palonosetron. Cancer Science, 2015, 106, 891-895.	3.9	39
98	Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. BMC Cancer, 2015, 15, 626.	2.6	13
99	Clinical impact of expanded <i>BRAF</i> mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2015, 33, 11038-11038.	1.6	1
100	The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan) Tj ETQq0 0 0 rgBT /Overlock 10 and non-colorectal gastrointestinal cancer (GI Screen 2013-01-CRC and 2015-01-Non CRC).. Journal of Clinical Oncology, 2015, 33, TPS4134-TPS4134.	1.6	1
101	Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR) Tj ETQq1 1 0.784314 rgBT /Overlock 10 573-573.	1.6	2
102	The nationwide genomic screening project for gastrointestinal cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01).. Journal of Clinical Oncology, 2015, 33, 578-578.	1.6	2
103	Association of early tumor shrinkage with progression-free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSC0802.. Journal of Clinical Oncology, 2015, 33, 749-749.	1.6	34
104	Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSC0802): Sub-group analysis by KRAS Exon2 status.. Journal of Clinical Oncology, 2015, 33, 782-782.	1.6	0
105	Analysis of the GERCOR index in KRAS Exon2 WT patients with mCRC treated with salvage-line cetuximab-based chemotherapy: HGCSC0901.. Journal of Clinical Oncology, 2015, 33, 781-781.	1.6	0
106	Phase II trial of irinotecan plus s-1 (IRIS) with cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS wild-type metastatic colorectal cancer (mCRC): HGCSC0902â€”Comparison of administration interval in cetuximab treatment.. Journal of Clinical Oncology, 2015, 33, 746-746.	1.6	1
107	Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSC0802.. Journal of Clinical Oncology, 2015, 33, 743-743.	1.6	0
108	Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSC1003): Detailed analysis of peripheral sensory neuropathy.. Journal of Clinical Oncology, 2015, 33, 701-701.	1.6	15

#	ARTICLE	IF	CITATIONS
109	Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSC0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV.. Journal of Clinical Oncology, 2015, 33, 527-527.	1.6	0
110	Evaluation of usefulness of Royal Marsden Hospital prognostic index in second-line chemotherapy of advanced gastric cancer.. Journal of Clinical Oncology, 2014, 32, 163-163.	1.6	1
111	Analysis of Kohne's prognostic index in KRAS wild-type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSC0901.. Journal of Clinical Oncology, 2014, 32, 634-634.	1.6	0
112	Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGCSC1001 (Japanese Skin Toxicity Evaluation Protocol with) Tj ETQq0 0 0 rgBT /Overclock 10 Tf 5	1.6	0
113	Comparison of adding cetuximab (Cmab) or panitumumab (Pmab) to irinotecan (IRI)-based chemotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSC0901 and 1002.. Journal of Clinical Oncology, 2014, 32, 598-598.	1.6	0
114	The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies.. Journal of Clinical Oncology, 2014, 32, 603-603.	1.6	0
115	Comparison of cetuximab (Cmab) with panitumumab (Pmab) monotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSC0901 and 1002.. Journal of Clinical Oncology, 2014, 32, 663-663.	1.6	4
116	Exploratory randomized trial to evaluate the effect of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV)/acute-onset diarrhea induced by IRIS/FOLFIRI: HGCSC0704.. Journal of Clinical Oncology, 2014, 32, 624-624.	1.6	0
117	Phase II trial of S-1 plus split cisplatin (SSP) in patients with advanced gastric cancer (HGCSC0702): Final report.. Journal of Clinical Oncology, 2014, 32, 113-113.	1.6	0
118	Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGSC1001 (Japanese Skin Toxicity Evaluation Protocol with) Tj ETQq0 0 0 rgBT /Overclock 10 Tf 5	1.6	0
119	Prognostic impact of human epidermal growth factor-2 (HER2) status on overall survival (OS) of advanced gastric cancer (AGC) patients (pts) treated with standard chemotherapy without trastuzumab as a first-line treatment: A Japanese multicenter collaborative retrospective study.. Journal of Clinical Oncology, 2013, 31, 4075-4075.	1.6	1
120	Randomized phase II study comparing dose-escalated weekly paclitaxel (wPTX) versus standard-dose wPTX for patients with previously treated advanced gastric cancer (AGC).. Journal of Clinical Oncology, 2013, 31, 64-64.	1.6	1
121	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysisâ€”Hokkaido Gastrointestinal Cancer Study Group (HGCSC) trial.. Journal of Clinical Oncology, 2013, 31, 460-460.	1.6	0
122	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSC) trialâ€”Comparison of the efficacy of KRAS status.. Journal of Clinical Oncology, 2013, 31, 536-536.	1.6	0
123	An open, multicenter, phase II clinical trial to evaluate efficacy and safety of S-1 split cisplatin in patients with advanced gastric cancer (AGC): HGCSC0702â€”Safety analysis.. Journal of Clinical Oncology, 2013, 31, 121-121.	1.6	0
124	Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: The HGCSC1002 studyâ€”Analysis of adverse events.. Journal of Clinical Oncology, 2013, 31, 554-554.	1.6	0
125	The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies.. Journal of Clinical Oncology, 2013, 31, e14604-e14604.	1.6	0
126	Randomized phase II study comparing dose-escalated weekly paclitaxel versus standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, 4076-4076.	1.6	7

#	ARTICLE	IF	CITATIONS
127	Randomized phase III clinical study comparing postoperative UFT/LV,UFT+LV/UFT and UFT+LV+PSK/UFT+PSK as adjuvant therapy for curatively resected stage III colorectal cancer HGCSG-CAD study.. Journal of Clinical Oncology, 2013, 31, 3638-3638.	1.6	1
128	Retrospective cohort study on the risk factors of admission due to serious adverse events during S-1 (tegafur, gimeracil, oteracil potassium) containing chemotherapy for gastric cancer.. Journal of Clinical Oncology, 2012, 30, 141-141.	1.6	0
129	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer: Update analysisâ€”Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.. Journal of Clinical Oncology, 2012, 30, 3593-3593.	1.6	0
130	NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	1